Literature DB >> 11855989

6-Sulfonylchromenes as highly potent K(ATP)-channel openers.

Ekkehart Salamon1, Raimund Mannhold, Horst Weber, Horst Lemoine, Walter Frank.   

Abstract

We synthesized K(ATP)-channel openers (KCOs) composed of the 4-pyridonechromene moiety of bimakalim (1) and a variety of sulfonyl-containing 6-substituents 4-29. Dilator potencies were measured in rat aorta and trachea. In both test systems the KCOs exhibit potency ranges of roughly 3 log units. The 6-N-phenyl-N-methylsulfonamido derivative 24 shows the highest potency. In rat aorta the potency spectrum ranges from a pEC(50) value of 8.76 to 5.68; in rat trachea it ranges from 8.01 to 4.99. On average, the dilator activity is about 0.8 log units stronger in the aorta. Aortic relaxation by chromene 13 is markedly retarded, the clinical relevance of which (e.g., preventing tachycardia) remains to be clarified. Binding affinities were determined in myocardial membranes and aortic smooth muscle cells of the rat. The affinity spectrum in myocardial membranes ranges from a pK(D) of 7.83 to 5.18; the highest affinity in aortic smooth muscle cells is measured for compound 28 (pK(D) = 8.55), whereas the lowest affinity is measured for 4 (pK(D) = 4.51). Significant selectivities discriminating between K(ATP)-channels of different organs could not be detected. PLS analysis yielded no significant correlation between vasodilator activity in aorta and chemical descriptors (GRIND). Compounds 13, 24, and 28 represent the most potent KCOs of the 4-pyridonechromene type published so far. Their 6-substituents exhibit a phenyl ring with a congruent conformational orientation in relation to the sulfonylchromene. From SAR data and conformational analysis we postulate that these new 6-substituents extend the binding site for chromene KCOs. Correspondingly, we assume that the receptor area exhibits two separate interaction sites with the capacity to bind 6-substituents: (a) one site interacting with negatively polarized partial structures (e.g., CN, NO(2), SO(2)) and (b) one spatially restricted site enabling favorable pi-interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855989     DOI: 10.1021/jm010999g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

2.  KATP channel openers of the benzopyran type reach their binding site via the cytosol.

Authors:  D Stephan; E Salamon; H Weber; U Russ; H Lemoine; U Quast
Journal:  Br J Pharmacol       Date:  2006-08-14       Impact factor: 8.739

Review 3.  Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies.

Authors:  Xi Wang; Yuanxun Wang; Xuemin Li; Zhenyang Yu; Chun Song; Yunfei Du
Journal:  RSC Med Chem       Date:  2021-08-10

4.  The expression of ATP-sensitive potassium channels in human umbilical arteries with severe pre-eclampsia.

Authors:  Benlan Yin; Yujiao Zhang; Xiaohong Wei; Chunrong Pang; Ting Hou; Chao Yang; Yuzhi Ning; Xiaodong Fu
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.